FDA says single-dose shot from J&J prevents severe COVID

An analysis by U.S. regulators says Johnson & Johnson's single-dose vaccine provides strong protection against severe COVID-19. An analysis by U.S. regulators says Johnson & Johnson's single-dose vaccine provides strong protection against severe COVID-19. |  Photo: Johnson & Johnson

LAURAN NEERGAARD and MATTHEW PERRONE
Updated: February 24, 2021 02:20 PM
Created: February 24, 2021 10:52 AM

WASHINGTON (AP) - An analysis by U.S. regulators says Johnson & Johnson's single-dose vaccine provides strong protection against severe COVID-19.

The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19.

On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot.

The FDA is expected to make a final decision within days.

If the FDA clears the J&J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.
 

Credits

LAURAN NEERGAARD and MATTHEW PERRONE

Copyright 2021 The Associated Press. All rights reserved.

8 people dead, others injured in overnight Indianapolis shooting

Breakthrough COVID-19 cases in Minnesota

More closures begin Monday for Can of Worms project

Minnesota COVID-19 Update Friday

Collar cam: Voyageurs Wolf Project gives rare perspective

No prom for Duluth schools due to COVID concerns